Amplity, Inc.

Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer

Health EN ↓ 6 episodes

We are pleased to present the exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer. This series provides peer-to-peer physician perspectives on emerging data in the treatment of hormone receptor (HR)-positive/HER2-negative early to metastatic breast cancer. Sponsored by Lilly

Author

Amplity, Inc.

Episodes

Part 6: Results From OptiTROP-Breast02 17.02.2026 12:40

We are pleased to present Part 6 , the final installment of an exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer . Part 6 of this series provides peer-to-peer physician perspectives on the results from the OptiTROP-Breast02 trial. Topics include: Results from OptiTROP-Breast02: Sacituzumab tirumotecan (sac-TMT) as a novel TROP2-directed antibody drug con...

Part 5: Results From TACTIVE-N 10.02.2026 13:51

We are pleased to present Part 5 of an exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer . Part 5 of this series provides peer-to-peer physician perspectives on the results from the TACTIVE-N trial. Topics include: Neoadjuvant vepdegestrant: results of TACTIVE-N trial Tolerance in next-generation endocrine therapies: PROTAC estrogen receptor degraders Di...

Part 4: First Results From VIKTORIA-1 04.02.2026 14:31

We are pleased to present Part 4 of an exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer . Part 4 of this series provides peer-to-peer physician perspectives on the first results from the VIKTORIA-1 trial. Topics include: Mechanisms of resistance to CDK4/6 inhibitors Rationale, design, and results of VIKTORIA-1 for the PIK3CA, wild-type cohort Discussant...

Part 3: Strategies for Staying on CDK4/6 Inhibitor Therapy 28.01.2026 7:58

We are pleased to present Part 3 of an exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer . Part 3 of this series provides peer-to-peer physician perspectives on strategies for staying on CDK4/6 inhibitor therapy. Topics include: Clinical trial experience managing adverse events of CDK4/6 inhibitors in early breast cancer Treatment persistence during real...

Part 2: Best Practices in Managing Early Breast Cancer With a High Risk of Recurrence 21.01.2026 8:44

We are pleased to present Part 2 of an exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer . Part 2 of this series provides peer-to-peer physician perspectives on best practices in managing early breast cancer. Topics include: Best practices in treating early HR-positive/HER2-negative breast cancer with a high risk of recurrence Balancing efficacy and qual...

Part 1: Long-Term Outcomes of Adjuvant CDK4/6 Inhibitors in HR-Positive/HER2-Negative Early Breast Cancer 14.01.2026 19:48

We are pleased to present Part 1 of an exclusive podcast, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer . Part 1 of this series provides peer-to-peer physician perspectives on emerging data in the adjuvant treatment of hormone receptor (HR)-positive/HER2-negative early breast cancer. Topics include: The role of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in the treatment...